Area of research
Oncology · Molecular Biology
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Biochemical and Molecular Research, Pancreatic and Hepatic Oncology Research, and Cancer Treatment and Pharmacology.
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the <i>DPYD</i>*2A variant: A matched pair analysis
Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update
Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma
Rs895819 in <scp><i>MIR27A</i></scp> improves the predictive value of <scp><i>DPYD</i></scp> variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
Translating <i>DPYD</i> Genotype into DPD Phenotype: Using the <i>DPYD</i> Gene Activity Score
The use of combinations of monoclonal antibodies in clinical oncology
RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth